Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

975 results about "Gene silencing" patented technology

Gene silencing is the regulation of gene expression in a cell to prevent the expression of a certain gene. Gene silencing can occur during either transcription or translation and is often used in research. In particular, methods used to silence genes are being increasingly used to produce therapeutics to combat cancer and diseases, such as infectious diseases and neurodegenerative disorders.

Methods and compositions for selecting siRNA of improved functionality

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Owner:THERMO FISHER SCIENTIFIC INC

Functional and hyperfunctional siRNA

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Owner:THERMO FISHER SCIENTIFIC INC

Methods, compositions and systems for local delivery of drugs

Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA / DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.
Owner:SILENSEED LTD

Gene silencing methods

Disclosed are methods for silencing a target nucleotide sequence (preferably representing one or more endogenous genes, preferably in a systemic fashion) which is present in a first part of the plant, which method comprises transiently introducing into the cytoplasm of a cell in a second part of the plant, which cell comprises a nucleic acid encoding the target sequence and which is remote from said first part of the plant, a nucleic acid construct.
Owner:PLANT BIOSCI LTD

Modified polynucleotides for reducing off-target effects in RNA interference

Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2′-O-alkyl or mismatch modification(s) at specific positions on the sense and / or antisense strands.
Owner:MERCK & CO INC +1

Generation of human embryonc stem-like cells using intronic RNA

ActiveUS20080293143A1Stable and relatively long-term effectDelivery stabilityOther foreign material introduction processesElectrical/wave energy microorganism treatmentReprogrammingMammal
This invention generally relates to a method for developing, generating and selecting human embryonic stem (hES)-like pluripotent cells using transgenic expression of intronic microRNA-like RNA agents. More particularly, the present invention relates to a method and composition for generating a non-naturally occurring intron and its intronic components capable of being processed into mir-302-like RNA molecules in mammalian cells and thus inducing certain specific gene silencing effects on differentiation-related and fate-determinant genes of the cells, resulting in reprogramming the cells into a pluripotent embryonic stem (ES)-cell-like state. The ES-like cells so obtained are strongly express hES cell markers, such as Oct3 / 4, SSEA-3 and SSEA-4, and can be guided into various tissue cell types by treating certain hormones and / or growth factors under a feeder-free cell culture condition in vitro, which may be used for transplantation and gene therapies. Therefore, the present invention offers a simple, effective and safe gene manipulation approach for not only reprogramming somatic cells into ES-like pluripotent cells but also facilitating the maintenance of pluripotent and renewal properties of ES cells under a feeder-free cell culture condition, preventing the tedious retroviral insertion of four large transcription factor genes into one single cell as used in the previous iPS methods.
Owner:MELLO BIOTECH +1

Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents

InactiveUS20090203141A1Improve target specificityReduce the number of copiesVectorsFermentationCancer cellMammal
The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On / Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA) / shRNA agent under the control of doxycyclin (Dox) in human somatic / cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.
Owner:LIN SHI LUNG +1

Methods and compositions for DNA mediated gene silencing

DNA compositions that mediate gene silencing via RNA interference are provided. Also provided are methods of using such compositions to silence gene expression in a cell.
Owner:ALLELE BIOTECH & PHARMA

siRNA-Mediated gene silencing with viral vectors

The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.
Owner:UNIV OF IOWA RES FOUND

Compositions of asymmetric interfering RNA and uses thereof

The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5′-overhang, 3′-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and / or therapeutics.
Owner:IGLOBE HEALTH INST LLC

MicroRNA vectors

The present invention relates to gene silencing, and in particular to compositions of microRNA sequences and vectors and to methods of synthesizing such in vitro and in vivo, and to methods of using such to regulate gene expression.
Owner:RGT UNIV OF MICHIGAN

siRNA targeting inner centromere protein antigens (INCENP)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.
Owner:THERMO FISHER SCIENTIFIC INC

Method for down-regulating gene expression in fungi

The present invention concerns methods for controlling fungus infestation via dsRNA mediated gene silencing, whereby the intact fungus cell(s) are contacted with a double-stranded RNA from outside the fungal cell(s) and whereby the double-stranded RNA is taken up by the intact fungal cell(s). In one particular embodiment, the methods of the invention are used to alleviate plants from fungus pests. Alternatively, the methods are used for treating and / or preventing fungal infestation on a substrate or a subject in need of such treatment and / or prevention. Suitable fungal target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed.
Owner:DEVGEN PTE LTD

siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
Owner:THERMO FISHER SCIENTIFIC INC

Exosome transfer of nucleic acids to cells

Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.
Owner:CODIAK BIOSCI

siRNA-mediated gene silencing with viral vectors

The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.
Owner:IOWA RES FOUND UNIV OF

siRNA targeting nucleoporin 62kDa (Nup62)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for Nup62.
Owner:THERMO FISHER SCIENTIFIC INC

siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.
Owner:THERMO FISHER SCIENTIFIC INC

Modified gene-silencing RNA and uses thereof

Methods and means for efficiently downregulating the expression of any gene of interest in eukaryotic cells and organisms are provided. To this end, the invention provides modified antisense and sense RNA molecules, chimeric genes encoding such modified antisense or sense RNA molecules and eukaryotic organisms such as plants, animals or fungi, yeast or molds, comprising the modified antisense and / or sense RNA molecules or the encoding chimeric genes.
Owner:COMMONWEALTH SCI & IND RES ORG

siRNA targeting protein kinase N-3 (PKN-3)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to PKN-3.
Owner:THERMO FISHER SCIENTIFIC INC

Methods and compositions for gene silencing

Methods and compositions are provided for reducing the level of expression of a target polynucleotide in an organism. The methods and compositions selectively silence the target polynucleotide through the expression of a chimeric polynucleotide comprising the target for a sRNA (the trigger sequence) operably linked to a sequence corresponding to all or part of the gene or genes to be silenced. In this manner, the final target of silencing is an endogenous gene in the organism in which the chimeric polynucleotide is expressed. In a further embodiment, the miRNA target is that of a heterologous miRNA or siRNA, the latter of which is coexpressed in the cells at the appropriate developmental stage to provide silencing of the final target when and where desired. In a further embodiment, the final target may be a gene in a second organism, such as a plant pest, that feeds upon the organism containing the chimeric gene or genes. Compositions further comprise vectors, seeds, grain, cells, and organisms, including plants and plant cells, comprising the chimeric polynucleotide of the invention.
Owner:PIONEER HI BRED INT INC +1

Mutiple gene expression for engineering novel pathways and hyperexpression of foreign proteins in plants

Introducing blocks of foreign genes in a single operon would avoid complications such as position effect and gene silencing inherent in putting one gene at a time into random locations in the nuclear genome. Cloning several genes into a single T-DNA does not avoid the compounded variable expression problem encountered in nuclear transgenic plants. This disclosure shows that a bacterial operon can be expressed in a single integration event as opposed to multiple events requiring several years to accomplish. Expression of multiple genes via a single transformation event opens the possibility of expressing foreign pathways or pharmaceutical proteins involving multiple genes. Expressing the Cry2aA2 operon, including a putative chaperonin to aid in protein folding, in the chloroplast via a single transformation event leads to production of crystalized insecticidal proteins. Expressing the Mer operon via a single transformation event leads to a phytoremediation system.
Owner:UNIV OF CENT FLORIDA RES FOUND INC +1

siRNA targeting tumor protein 53 (p53)

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
Owner:THERMO FISHER SCIENTIFIC INC

Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same

Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Certain Plants with "No Saturate" or Reduced Saturate Levels of Fatty Acids in Seeds, and Oil Derived from the Seeds

The subject invention provides “no sat” canola oil. The subject invention also provides seeds that can be used to produce such oils. Plants that produce these seeds are also included within the subject invention. All of this was surprisingly achieved by using a delta-9 desaturase gene in canola. This technology can be applied to other plants as disclosed herein. Oils of the subject invention have particularly advantageous characteristics and fatty acid profiles, which were not heretofore attained. The subject invention still further provides a plant-optimized delta-9 desaturase gene. The subject invention still further provides a plant-optimized delta-9 desaturase gene. In some preferred embodiments, a preferred plant comprises at least two copies of a delta-9 desaturase gene of the subject invention. Seeds produced by such plants surprisingly do not exhibit effects of gene silencing but rather have further surprising reductions in levels of total saturates.
Owner:CORTEVA AGRISCIENCE LLC

Method for transforming rice into fragrant rice rapidly

The invention discloses a method for transforming rice into fragrant rice rapidly. By means of the CRISPR / Case technology and related gene sequences in the rice fragrance metabolic process, a carrier is designed at the specific site, the element is transferred to non-fragrant rice through agrobacterium-mediated transformation, the gene is made to cause deletion mutation at the position of a fixed point, the gene is silent, fragrance cannot be normally metabolized and greatly accumulated, common rice is transformed into fragrant rice, then genetic transformation gene segments are separated from edited genes through selfing or hybridization, and the fragrant rice with the isozygoty capable of being stably inherited is rapidly obtained.
Owner:NINGXIA ACADEMY OF AGRI & FORESTRY SCI

Method for treating prostate cancer using siRNA duplex for androgen receptor

InactiveUS20050164970A1Increased caspase- activationVirusesSugar derivativesAndrogen Receptor GeneGene silencing
Interfering RNA duplexes directed to the androgen receptor associated with prostate cancer are provided. A method of treating prostate cancer using interfering RNA duplexes to mediate gene silencing is also provided.
Owner:UNIV KANSAS MEDICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products